Today, we published a Quarterly Update on GenSpera, Inc., a biotechnology company developing targeted prodrugs for prostate and other cancers. The Company’s prodrug technologies were developed over 15 years at Johns Hopkins and other global research centers and funded by over $15 million in grants from the U.S. National Institutes of Health, the National Cancer Institute, and the U.S. Department of Defense, among others.
A Phase I safety trial evaluating the Company’s lead prodrug candidate, G-202, in solid tumors is ongoing at three major cancer centers:
- the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, Maryland;
- the University of Wisconsin Carbone Cancer Center in Madison, Wisconsin; and
- the Cancer Therapy and Research Center (CTRC) at the University of Texas Health Science Center at San Antonio (UTHSCSA) in San Antonio, Texas.
To date, 16 patients have been enrolled and dosed in the Phase I study with G-202. The Company has the option to expand the trial to include 18 additional patients in a Phase Ib cohort at the maximum tolerated dose of G-202. Data from this cohort could provide an early signal of potential activity in multiple cancer types.
GenSpera’s pipeline is developing two additional prodrugs G-115 and G-301 (formerly Ac-GKAFRR-L12ADT), which directly target prostate cancer. The Company aims to obtain an Investigational New Drug (IND) for G-115 in the second half of 2011.
GenSpera has raised a total of $6.2 million to date in 2011, which is being used to support a Phase II clinical program with G-202 as well as the preclinical development of G-115. The Company owns and controls all rights to G-202, G-115, and G-301, and seeks strategic partnerships to maximize the value of its prodrugs.
A more detailed overview of GenSpera, as well as a summary of the Company’s stock information, is available through our Research Library.